Barclays PLC Harvard Bioscience Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Barclays PLC holds 58,655 shares of HBIO stock, worth $125,521. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,655

Previous 14,505 304.38%

Holding current value

$125,521

Previous $42,000 273.81%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.64 - $3.54 $116,556 - $156,291	44,150 Added 304.38%	58,655 $157,000
Q2 2024 Aug 14, 2024	SELL	$2.77 - $4.63 $39,201 - $65,523	-14,152 Reduced 49.38%	14,505 $42,000
Q1 2024 May 15, 2024	SELL	$4.02 - $5.39 $109,106 - $146,289	-27,141 Reduced 48.64%	28,657 $121,000
Q4 2023 Feb 15, 2024	BUY	$4.0 - $5.49 $194,452 - $266,885	48,613 Added 676.59%	55,798 $299,000
Q3 2023 Nov 07, 2023	SELL	$4.0 - $5.82 $2,588 - $3,765	-647 Reduced 8.26%	7,185 $31,000
Q2 2023 Aug 03, 2023	BUY	$4.19 - $6.16 $32,816 - $48,245	7,832 New	7,832 $43,000
Q3 2022 Nov 03, 2022	BUY	$2.33 - $3.92 $111 - $188	48 New	48 $0
Q2 2022 Aug 12, 2022	SELL	$3.28 - $6.42 $20,919 - $40,946	-6,378 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.16 - $7.14 $213,144 - $294,931	-41,307 Reduced 86.62%	6,378 $40,000
Q4 2021 Feb 14, 2022	BUY	$6.37 - $8.18 $201,476 - $258,725	31,629 Added 196.99%	47,685 $337,000
Q3 2021 Nov 09, 2021	BUY	$6.98 - $8.47 $75,872 - $92,068	10,870 Added 209.6%	16,056 $112,000
Q2 2021 Aug 13, 2021	SELL	$5.44 - $8.4 $145,895 - $225,279	-26,819 Reduced 83.8%	5,186 $44,000
Q1 2021 May 13, 2021	BUY	$3.91 - $6.99 $63,865 - $114,174	16,334 Added 104.23%	32,005 $174,000
Q4 2020 Feb 11, 2021	SELL	$3.0 - $4.5 $5,340 - $8,010	-1,780 Reduced 10.2%	15,671 $67,000
Q3 2020 Nov 12, 2020	SELL	$2.75 - $4.2 $40,400 - $61,702	-14,691 Reduced 45.71%	17,451 $52,000
Q2 2020 Aug 12, 2020	BUY	$2.12 - $3.14 $68,141 - $100,925	32,142 New	32,142 $100,000
Q4 2019 Feb 10, 2020	SELL	$2.45 - $3.25 $78 - $104	-32 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.59 - $3.47 $119,393 - $260,562	-75,090 Reduced 99.96%	32 $0
Q2 2019 Aug 14, 2019	BUY	$1.93 - $4.59 $123,095 - $292,750	63,780 Added 562.33%	75,122 $150,000
Q1 2019 May 15, 2019	BUY	$2.77 - $4.38 $27,952 - $44,198	10,091 Added 806.63%	11,342 $48,000
Q4 2018 Feb 14, 2019	SELL	$3.03 - $5.0 $45,022 - $74,295	-14,859 Reduced 92.23%	1,251 $4,000
Q3 2018 Nov 14, 2018	BUY	$5.0 - $6.65 $67,660 - $89,987	13,532 Added 524.9%	16,110 $85,000
Q2 2018 Aug 14, 2018	SELL	$4.2 - $5.95 $11,016 - $15,606	-2,623 Reduced 50.43%	2,578 $14,000
Q1 2018 May 15, 2018	BUY	$3.3 - $5.15 $17,163 - $26,785	5,201 New	5,201 $26,000

Others Institutions Holding HBIO

# of Institutions

Shares Held

30.6M

Call Options Held

700

Put Options Held

2.1K

View Full List

About HARVARD BIOSCIENCE INC

Ticker HBIO
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 41,636,500
Market Cap $89.1M
Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...

More about HBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account